Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05477693
Other study ID # PRO-PPV-4002
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 25, 2022
Est. completion date April 10, 2023

Study information

Verified date April 2022
Source Sinovac Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in population aged 2 years and older.


Description:

This study is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial to evaluate the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in population aged 2 years and older.The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd,the control vaccine was manufactured by Merck Sharp & Dohme.A total of 1800 subjects including 900 subjects aged 2~17 years,360 subjects aged 18~59 years and 540 subjects aged 60 years and above will be enrolled.Subjects in each age group will be randomly divided into two groups according to the ratio of 2:1, and received one dose of experimental vaccine or control vaccine.


Recruitment information / eligibility

Status Completed
Enrollment 1800
Est. completion date April 10, 2023
Est. primary completion date April 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Children aged 2 years and above in stable health; - The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form.If the subject aged 16 to 17 years with full capacity for civil conduct and his/her labor income is his/her main source of living, the informed consent can be signed only by the subject himself/herself); - Proven legal identity. Exclusion Criteria: - Have received any pneumococcal vaccine; - History bacterial pneumonia or invasive pneumococcal infectious diseases caused by pneumococci and confirmed by culture. - Women of childbearing age (menarche to premenopause) are pregnant (including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month; - History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; - Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure =140mmHg and/or diastolic blood pressure =90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.; - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; - A long history of alcohol or drug abuse; - Receipt of blood products within in the past 3 months; - Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine; - Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Onset of various acute or chronic diseases within 3 days prior to the study; - Underarm body temperature before vaccination>37.0°C; - The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials within 1 months; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Experimental 23-valent PPV
The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25µg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
Control 23-valent PPV
The control vaccine was manufactured by Merck Sharp & Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.

Locations

Country Name City State
China Linwei District Center for Disease Control and Prevention Weinan Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity index-Seroconversion rate (2-fold increase rate) Seroconversion rate (2-fold increase rate)for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal immunoglobulin G (IgG) antibody 30 days after vaccination. 30 days after vaccination
Secondary Immunogenicity index-Geometric Mean Concentration (GMC) Geometric Mean Concentration (GMC) for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal IgG antibody 30 days after vaccination. 30 days after vaccination
Secondary Immunogenicity index-Geometric Mean Increase (GMI) Geometric Mean Increase (GMI) for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal IgG antibody 30 days after vaccination. 30 days after vaccination
Secondary Immunogenicity index-Seroconversion rate Seroconversion rate for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination. 30 days after vaccination
Secondary Immunogenicity index-GMC Geometric Mean Concentration (GMC) for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination. 30 days after vaccination
Secondary Immunogenicity index-GMI Geometric Mean Increase (GMI) for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination. 30 days after vaccination
Secondary Safety index-Incidence of adverse reactions Incidence of adverse reactions within 30 days after vaccination. Within 30 days after vaccination
Secondary Safety index-incidence of adverse reactions Incidence of adverse reactions within 7 days after vaccination Within 7 days after vaccination
Secondary Safety index-Incidence of serious adverse events Incidence of serious adverse events within 30 days after vaccination. Within 30 days after vaccination
See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT02116998 - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae Phase 2
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2